New RSV Vaccine Approved For Infants

New RSV Vaccine Approved For Infants

The Food and Drug Administration this month approved a new vaccine for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants, designed as preventive care for their first RSV season. The long-acting monoclonal antibody clesrovimab-cfor offers protection through 5 months with the same 105 mg dose regardless of weight, according to a press release from manufacturer Merck. Clinical data from multiple trials shows significant reductions in RSV incidence and …

Read More
All Adults Over 75 Should Get RSV Vaccine: CDC 

All Adults Over 75 Should Get RSV Vaccine: CDC 

The Centers for Disease Control and Prevention (CDC) recently updated vaccine guidance after its advisory committee recommended that all adults aged 75 years and older and adults aged 60–74 years who are at increased risk should receive a single dose of a respiratory syncytial virus (RSV) vaccine. The update reflects CDC’s intent to maximize RSV vaccination coverage among those most likely to benefit and to reduce implementation barriers associated with a previous recommendation that called …

Read More